03/17/2026
We’re grateful to be part of continued progress in kidney care.
The Wichita Nephrology Clinical Research Institute contributed to the Phase III FIND-CKD clinical trial evaluating KERENDIA® (finerenone), which has met its primary endpoint—marking an important step forward for patients living with non-diabetic chronic kidney disease.
We would also like to recognize Dr. Jany Moussa, who served as the Primary Investigator for our site. His leadership and commitment to advancing clinical research continue to make a meaningful impact.
Thankful for our dedicated research team and especially for the patients who participate in clinical trials—none of this work is possible without them.
KERENDIA® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate.